Stoke Therapeutics (STOK) Revenue Growth (1y) (2023 - 2026)
Stoke Therapeutics (STOK) Revenue Growth (1y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,538.84 Bn | 65,538.56 Bn | - | - |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 469.46 Bn | 464.67 Bn | 1.35 Bn | 35.46% |
| 5 | Vertex Pharmaceuticals | 122.69 Bn | 115.45 Bn | 2.59 Bn | 7.82% |
| 6 | Regeneron Pharmaceuticals | 70.41 Bn | 61.65 Bn | 3.31 Bn | 19.04% |
| 7 | Belite Bio | 62.84 Bn | 62.84 Bn | - | - |
| 8 | Argenx Se | 56.10 Bn | 50.91 Bn | 1.41 Bn | 64.03% |
| 9 | Alnylam Pharmaceuticals | 37.48 Bn | 34.47 Bn | 959.66 Mn | 96.43% |
| 10 | Stoke Therapeutics | 1.86 Bn | 1.52 Bn | - | -96.07% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -96.07% |
| Dec 31, 2025 | -93.80% |
| Sep 30, 2025 | 117.25% |
| Jun 30, 2025 | 186.01% |
| Mar 31, 2025 | 3,661.12% |
| Dec 31, 2024 | 707.07% |
| Sep 30, 2024 | 47.94% |
| Jun 30, 2024 | 94.72% |
| Mar 31, 2024 | -18.17% |
| Dec 31, 2023 | -14.26% |
| Sep 30, 2023 | 13.87% |
| Jun 30, 2023 | -23.21% |
| Mar 31, 2023 | 71.73% |